Bristol Myers Squibb's Dual Phase 3 Success Strengthens Drug Pipeline Ahead of Patent Expirations

Two Clinical Trial Wins Bring New Momentum to Bristol Myers Squibb

Bristol Myers Squibb (BMY) announced positive results from two late-stage clinical trials on Monday, October 12, advancing experimental treatments for rare neuroendocrine tumors and idiopathic pulmonary fibrosis, a progressive lung disease.

The announcements involve RYZ101, a targeted radioactive cancer therapy, and admilparant, an oral treatment designed to slow lung scarring. Both studies met their primary endpoints, providing encouraging clinical evidence as Bristol Myers works to develop new revenue sources ahead of major patent expirations.

The news initially lifted BMY stock, with reports showing gains ranging from approximately 2% to 6.5% during Monday's session. Other market snapshots subsequently showed shares trading lower, reflecting a changing intraday reaction.

Key Points

• RYZ101 met its Phase 3 primary endpoint, significantly improving progression-free survival in patients with advanced neuroendocrine tumors whose cancer progressed after earlier radioactive treatment.
• Admilparant slowed lung-function decline in a Phase 3 pulmonary fibrosis study at the lower tested dose, although the higher dose did not achieve statistical significance.
• The results strengthen Bristol Myers' development pipeline ahead of major patent expirations, but regulatory approvals, commercial timing and the full magnitude of clinical benefits remain uncertain.

RYZ101 Delivers Positive Results in Advanced Neuroendocrine Tumors

Bristol Myers Squibb reported that its Phase 3 ACTION-1 trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival among patients receiving RYZ101.

Progression-free survival measures how long patients remain alive without their cancer worsening.

The trial evaluated patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, or GEP-NETs, whose disease had progressed following treatment with a lutetium-177-based radiopharmaceutical.

These relatively rare cancers develop in the gastrointestinal tract or pancreas. Approximately 18,000 new cases are diagnosed annually in the United States.

Although existing radioactive treatments can provide meaningful clinical benefits, many patients eventually experience disease progression, leaving limited subsequent treatment options.

ACTION-1 compared RYZ101 against standard treatments selected by investigators, including somatostatin analogues, everolimus and sunitinib.

The trial's planned interim analysis found that patients receiving RYZ101 experienced a meaningful improvement in progression-free survival compared with those receiving standard care.

The results were assessed through blinded independent central review, meaning the evaluation was conducted independently without reviewers knowing which treatments patients received.

Safety findings were consistent with RYZ101's previously established profile.

RYZ101 uses actinium-225, a radioactive isotope that emits high-energy alpha particles, to deliver targeted radiation to cancer cells.

This differs from earlier lutetium-177-based treatments and represents an emerging approach within cancer therapy.

The drug originated with RayzeBio, which Bristol Myers acquired for approximately $4.1 billion.

The positive ACTION-1 results provide important clinical support for that acquisition and the company's broader investment in radiopharmaceutical development.

RYZ101 received Orphan Drug Designation from the U.S. Food and Drug Administration in August 2026, recognizing its development for a rare disease.

Bristol Myers plans to meet with the FDA to discuss the trial findings and potential steps toward a regulatory submission.

However, the company has not yet disclosed detailed progression-free survival figures or a regulatory filing date.

Patients enrolled in the study will continue to be followed for overall survival, which measures how long patients live regardless of whether their cancer progresses.

Detailed results are expected at a future medical meeting.

Why Is Admilparant's Pulmonary Fibrosis Trial Important?

Bristol Myers also announced positive results from its Phase 3 ALOFT-IPF study evaluating admilparant in adults with idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis, or IPF, is a chronic lung disease characterized by progressive scarring of lung tissue.

As the scarring advances, the lungs become less capable of functioning normally, leading to worsening breathing difficulties.

Admilparant is an experimental oral medication that blocks lysophosphatidic acid receptor 1, commonly called LPA1.

This biological pathway is involved in processes associated with tissue scarring.

By targeting LPA1, researchers are investigating whether the drug can slow the progression of pulmonary fibrosis.

The ALOFT-IPF trial evaluated two doses of admilparant against placebo over 52 weeks.

Its primary endpoint measured changes in forced vital capacity, or FVC, which represents the amount of air a person can forcibly exhale after taking a full breath.

FVC is commonly used to assess the progression of pulmonary fibrosis.

Patients receiving admilparant at 60 milligrams twice daily experienced a statistically significant reduction in lung-function decline compared with placebo.

Importantly, the finding demonstrates slower deterioration in lung function rather than an overall improvement from patients' initial lung-function measurements.

The higher 120-milligram twice-daily dose also showed slower decline, but the difference compared with placebo did not achieve statistical significance.

That distinction leaves questions about how treatment effectiveness varies across doses.

Safety results were encouraging, with the company reporting favorable tolerability in both treatment groups.

Discontinuations caused by adverse events remained low and were comparable with those observed in the placebo group.

Bristol Myers is reviewing the complete dataset before engaging with global health authorities regarding potential regulatory submissions.

The company is also conducting another Phase 3 study, ALOFT-PPF, involving patients with progressive pulmonary fibrosis.

That trial is fully enrolled, with initial results expected in early 2027.

The findings from ALOFT-IPF also attracted attention beyond Bristol Myers.

Contineum Therapeutics (CTNM) is developing PIPE-791, another experimental drug targeting the LPA1 pathway.

Its candidate remains in Phase 2 clinical development.

Contineum shares initially surged in premarket trading following Bristol Myers' announcement but subsequently reversed course and declined sharply during Monday's session.

The reaction highlighted both the potential significance of Bristol Myers' findings for the broader LPA1 drug class and the uncertainty surrounding individual drug candidates.

Positive results for admilparant do not establish the effectiveness or safety of Contineum's separate treatment.

Clinical Progress Strengthens Pipeline as Patent Expirations Approach

The two Phase 3 announcements come at an important point in Bristol Myers Squibb's efforts to develop new products.

The pharmaceutical company faces significant patent expirations affecting major revenue-generating medicines.

Key protections for Opdivo and Eliquis begin expiring in 2028.

Eliquis is co-commercialized with Pfizer (PFE).

These patent expirations create pressure for Bristol Myers to develop and commercialize newer treatments capable of supporting future revenue.

The company has been expanding its growth portfolio through internal drug development and acquisitions.

One important product in that effort is Cobenfy, an antipsychotic medication that has experienced a slower-than-expected commercial launch and clinical setbacks.

The positive RYZ101 and admilparant results add two distinct potential opportunities to the company's late-stage pipeline.

RYZ101 targets patients with advanced cancers who have limited treatment options after earlier radiopharmaceutical therapy.

Admilparant addresses progressive lung disease through a different biological mechanism.

The clinical successes are meaningful, but neither product has received regulatory approval for the indications described in these studies.

The complete treatment-effect data also remain unavailable.

For RYZ101, the magnitude and durability of the progression-free survival benefit, together with longer-term overall survival results, will help establish the treatment's clinical profile.

For admilparant, the difference between the statistically successful lower dose and the unsuccessful higher-dose result requires further examination.

Commercial considerations will also matter, including manufacturing capacity, reimbursement, competitive positioning and the timing of any eventual launches.

The supplied reporting does not establish an immediate earnings benefit from either announcement or demonstrate that future revenue from these therapies will offset losses associated with expiring product protections.

Bristol Myers' stock reaction reflected the importance investors placed on the positive trial findings.

However, the differing intraday price reports indicate that the initial enthusiasm was not sustained consistently throughout Monday's trading.

What It Means for Investors

Bristol Myers Squibb's dual Phase 3 success provides new clinical evidence supporting two potential additions to its future commercial portfolio.

For a pharmaceutical company facing major patent expirations, late-stage drug development results are particularly important because they can clarify which experimental products may eventually become approved treatments.

RYZ101 represents an opportunity in targeted radiopharmaceutical cancer therapy, an area that has attracted increasing industry attention.

Its successful Phase 3 interim analysis provides support for Bristol Myers' investment in RayzeBio and its actinium-based treatment platform.

Admilparant offers a separate opportunity in pulmonary fibrosis, where slowing disease progression is an important treatment objective.

Its positive lower-dose findings also provide clinical evidence supporting the LPA1 pathway as a therapeutic target.

Nevertheless, statistical success in a clinical trial does not automatically translate into regulatory approval or commercial success.

The detailed results will be important for understanding the actual size of the treatment benefits and the consistency of the findings.

Investors will also have additional information to evaluate when Bristol Myers discusses RYZ101 with the FDA, releases complete admilparant data and reports results from the ALOFT-PPF trial in early 2027.

The announcements strengthen the company's late-stage development outlook, while the financial implications remain dependent on further clinical evaluation, regulatory decisions and eventual commercialization.

Conclusion

Bristol Myers Squibb delivered two important clinical developments with positive Phase 3 results for RYZ101 and admilparant.

RYZ101 significantly improved progression-free survival in patients with advanced neuroendocrine tumors, while admilparant demonstrated a statistically significant reduction in lung-function decline at its lower tested dose in idiopathic pulmonary fibrosis.

Both programs provide potential new treatment opportunities as Bristol Myers prepares for patent expirations affecting major existing products.

The results also bring new attention to targeted radiopharmaceuticals and LPA1 inhibitors as emerging areas of pharmaceutical development.

The next milestones will involve detailed clinical findings, regulatory discussions and additional study results.

For Bristol Myers, the central question is whether these promising late-stage developments can ultimately become approved treatments that contribute meaningfully to its future growth.

FAQs

Why did Bristol Myers Squibb stock initially rise on October 12, 2026?

Bristol Myers Squibb shares initially rose following positive Phase 3 clinical trial results for RYZ101 and admilparant. Both treatments met their primary study endpoints, strengthening the company's late-stage drug development pipeline. Later market snapshots showed shares trading lower.

What is RYZ101, and what did its Phase 3 trial show?

RYZ101 is an investigational targeted radiopharmaceutical cancer therapy using actinium-225. Its Phase 3 ACTION-1 trial demonstrated a statistically significant and clinically meaningful improvement in progression-free survival among patients with advanced neuroendocrine tumors whose disease progressed after earlier lutetium-177-based treatment.

What did the admilparant Phase 3 trial demonstrate?

The ALOFT-IPF trial showed that admilparant at 60 milligrams twice daily significantly slowed lung-function decline compared with placebo in patients with idiopathic pulmonary fibrosis. The higher 120-milligram dose also slowed decline but did not achieve statistical significance.

Are RYZ101 and admilparant approved treatments?

No. Both RYZ101 and admilparant remain investigational treatments. Bristol Myers Squibb plans to engage with regulatory authorities regarding potential submissions, but neither program has a disclosed filing date in the supplied reporting.

What are the next clinical milestones for Bristol Myers Squibb?

Bristol Myers plans to discuss RYZ101 with the FDA and present detailed results from both Phase 3 programs at future medical meetings. The company also expects initial results from its ALOFT-PPF study of admilparant in progressive pulmonary fibrosis in early 2027.

This article was created with AI assistance and reviewed by an editor. For details, please refer to our Terms of Use.

Go Beyond the Market Brief with Market Edge

Follow SharperTrades’ complete approach to trading and investing, combining active trade opportunities through Block Orders, long-term research through Stock Investor, and structured market education through the Swing Trading Masterclass. Try Market Edge for $19 your first month →

Explore Research with Stock Investor

Stock Investor is SharperTrades’ platform for long-term investing research and portfolio management. Members receive research reports, portfolio updates, conviction tracking, and in-depth analysis designed to support disciplined investment decisions.

Explore Active Trading & Income Strategies

Block Orders tracks institutional activity and highlights active trade setups and price behavior across long and short opportunities.

For options-focused traders, Essential Option Income provides a structured approach to options income strategies, while Pro Option Trader offers a broader range of options strategies and trade opportunities.

Think More Clearly with SteadyCapital

SteadyCapital is SharperTrades’ decision-support system for long-term investors, built around the SteadyCapital Method™. Review investment ideas, challenge assumptions, evaluate valuation and risk, compare companies, and think through important buy, hold, add, trim, or sell decisions before you act.

Risk Disclosure

All content is provided for educational purposes only and does not constitute investment advice. Trading involves risk, and past performance is not indicative of future results. Please review our full Risk Disclosure for additional information.